Quanterix is a leader in ultra-sensitive biomarker detection, using its proprietary Simoa™ (Single Molecule Array) technology to measure proteins at concentrations up to 1,000 times lower than traditional immunoassays. This breakthrough enables the detection and quantification of biomarkers that were previously challenging or impossible to measure. This advancement opens new avenues in life science research, in-vitro diagnostics, companion diagnostics, and blood screening. Their latest innovation, Simoa® Advantage PLUS, enhances assay consistency and sustainability for large-scale studies. Quanterix holds exclusive rights to a broad IP portfolio developed by Dr. David Walt at Tufts University, co-founder of Quanterix and Illumina.